Table 2 Unadjusted and adjusted odds ratios and 95% confidence intervals (CI) for sustained virological response after treatment with peginterferon and ribavirin in 432 chronically HCV infected patients, according to predictor variables
Predictor variable | Odds ratio (95% CI) unadjusted | Odds ratio (95% CI) adjusted | |
|---|---|---|---|
Gender | Female | 1 | 1 |
Male | 0.92 (0.61-1.39) | 0.80 (0.50-1.27) | |
Nationality | European | 1 | 1 |
Non-European | 2.53 (1.23-5.21) | 3.03 (1.20-7.67) | |
Route of infection | Non-IDU | 1 | 1 |
IDU | 1.59 (0.91-2.77) | 1.43 (0.76-2.69) | |
Unknown | 1.38 (0.77-2.49) | 1.21 (0.61-2.41) | |
Age | Age ≤ 45 years at treatment initiation | 1 | 1 |
Age > 45 years at treatment initiation | 0.38 (0.25-0.58) | 0.47 (0.30-0.74) | |
Genotype | 1 | 1 | 1 |
2 or 3 | 3.01 (1.97-4.60) | 2.31 (1.45-3.69) | |
HCV-RNA | ≤ 600.000 IU/mL | 1 | 1 |
> 600.000 IU/mL | 0.53 (0.36-0.79) | 0.70 (0.45-1.10) | |
ALT | Less than 2 × UNL* | 1 | 1 |
More than 2 × UNL | 1.39 (0.94-2.06) | 1.40 (0.91-2.16) | |
Treating department (speciality) | Gastroenterology/Hepatology | 1 | 1 |
Infectious Diseases | 1.03 (0.69-1.55)) | 0.93 (0.59-1.49) | |
Liver biopsy | Not cirrhosis | 1 | |
Cirrhosis | 0.44 (0.25-0.79) § | ||
Treatment completion | As shceduled | 1 | 1 |
With dose reduction | 0.55 (0.34-0.90) | 0.57 (0.33-0.96) | |
Ended before scheduled | 0.22 (0.12-0.38) | 0.26 (0.14-0.47) |